1. Home
  2. VSTD vs INDP Comparison

VSTD vs INDP Comparison

Compare VSTD & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VSTD

Vestand Inc.

HOLD

Current Price

$0.38

Market Cap

5.4M

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.78

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTD
INDP
Founded
2016
2000
Country
United States
United States
Employees
259
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
5.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VSTD
INDP
Price
$0.38
$1.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
41.0K
51.9K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.27
52 Week High
$2.20
$13.24

Technical Indicators

Market Signals
Indicator
VSTD
INDP
Relative Strength Index (RSI) 53.26 34.21
Support Level $0.32 $1.71
Resistance Level $0.41 $2.08
Average True Range (ATR) 0.03 0.30
MACD -0.01 -0.18
Stochastic Oscillator 37.21 1.13

Price Performance

Historical Comparison
VSTD
INDP

About VSTD Vestand Inc.

Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: